Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

USPSTF Draft Statement recommends biennial screening mammography for women ages 40 to 74 years

22 May, 2023 | 13:56h | UTC

Breast Cancer: Screening – U.S. Preventive Services Task Force

Critical perspectives on the statement:

Earlier screening for breast cancer: Benefits and harms – Lown Institute

Video: Mammography – Does it save lives? | The USPSTF is incorrect | I review ALL the data – By Dr. Vinay Prasad

Why more mammograms aren’t the solution to breast cancer – Vox

 

ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy

22 May, 2023 | 13:27h | UTC

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Commentary: Guideline Update Provides New Testing and Treatment Recommendations for Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Mutations – ASCO Daily News

 

Cohort Study | Following lifestyle recommendations linked to lower recurrence in high-risk breast cancer

15 May, 2023 | 12:48h | UTC

Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer – JAMA Network Open

Commentary: Adherence to healthy lifestyle found to cut breast cancer recurrence, mortality – HealthDay

 

Commentary on Twitter

 

Uncertainties and controversies in axillary management of patients with breast cancer

11 May, 2023 | 11:53h | UTC

Uncertainties and controversies in axillary management of patients with breast cancer – Cancer Treatment Reviews

 

Single-arm study | Halting endocrine therapy for pregnancy not linked to increased breast cancer events vs. a control cohort

10 May, 2023 | 16:01h | UTC

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not Increase Short-Term Risk for Worsening Breast Cancer Outcomes – ESMO

 

Commentary on Twitter

 

New ACR breast cancer screening guidelines call for earlier and more-intensive screening for high-risk women

9 May, 2023 | 14:50h | UTC

News Release: New ACR Breast Cancer Screening Guidelines call for earlier and more-intensive screening for high-risk women – American College of Radiology

Guideline: Breast Cancer Screening for Women at Higher-than-Average Risk: Updated Recommendations from the ACR

 

Effects of intraoperative fluorescence guidance for breast cancer lumpectomy surgery

9 May, 2023 | 14:48h | UTC

Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery – NEJM Evidence

News Release: Study finds fluorescent guide can help detect tumor left behind after breast cancer surgery – Mass General Brigham

 

RCT | Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor–positive breast cancer

9 May, 2023 | 14:32h | UTC

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor–Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

M-A | Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer

9 May, 2023 | 14:24h | UTC

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis – ESMO Open

 

M-A | Quality of life after risk-reducing surgery for breast and ovarian cancer prevention

9 May, 2023 | 14:21h | UTC

Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis – American Journal of Obstetrics and Gynecology

 

Review | Cancer treatment-related cardiovascular toxicity in gynecologic malignancies

26 Apr, 2023 | 14:14h | UTC

Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review – JACC: CardioOncology

 

Commentary on Twitter

 

RCT | Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer

26 Apr, 2023 | 13:57h | UTC

Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

RCT | 10-year results show low-dose tamoxifen reduces noninvasive breast cancer recurrence

17 Apr, 2023 | 12:50h | UTC

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Low-Dose Tamoxifen to Prevent Recurrence in Patients With Breast Noninvasive Neoplasia: 10-Year Follow-up of TAM-01 Trial – The ASCO Post

 

RCT | Exploring the potential of peritumoral lidocaine infiltration to improve outcomes in early breast cancer

11 Apr, 2023 | 14:37h | UTC

Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer – Journal of Clinical Oncology

 

SR | Insufficient evidence on skin-sparing mastectomy efficacy and safety for breast cancer

6 Apr, 2023 | 13:04h | UTC

Skin‐sparing mastectomy for the treatment of breast cancer – Cochrane Database of Systematic Reviews

Summary: Is skin-sparing mastectomy an effective and safe surgical procedure for the treatment of breast cancer? – Cochrane Database of Systematic Reviews

 

Review | Comprehensive care of women with genetic predisposition to breast and ovarian cancer

5 Apr, 2023 | 13:32h | UTC

Comprehensive Care of Women With Genetic Predisposition to Breast and Ovarian Cancer – Mayo Clinic Proceedings

 

SR | Adding ultrasound to mammography increases breast cancer detection, but increases false-positives and biopsies

3 Apr, 2023 | 13:55h | UTC

Summary: The systematic review examined the effectiveness and safety of combining mammography with breast ultrasonography versus mammography alone for breast cancer screening in women at average risk. The research included one randomized controlled trial, two prospective cohort studies, and five retrospective cohort studies, involving a total of 209,207 women.

High certainty evidence from one trial indicated that combining mammography with ultrasonography led to the detection of more breast cancer cases than mammography alone (5 vs. 3 per 1000 women). However, this combination also led to a higher number of false-positive results and biopsies. For every 1000 women screened with the combined approach, 37 more received a false-positive result, and 27 more women underwent a biopsy.

Secondary analysis of the trial data revealed that in women with dense breasts, the combined screening detected more cancer cases than mammography alone, while cohort studies for women with non-dense breasts showed no statistically significant difference between the two screening methods.

The included studies did not analyze whether the higher number of detected cancers with the combined screening method resulted in lower mortality rates compared to mammography alone. Further research, including randomized controlled trials or prospective cohort studies with longer observation periods, is needed to assess the impact of the two screening interventions on morbidity and mortality.

Article: Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk – Cochrane Database of Systematic Reviews

Summary: Mammography followed by ultrasonography compared to mammography alone for breast cancer screening in women at average risk of breast cancer – Cochrane Database of Systematic Reviews

 

RCT | Comparing exemestane dose regimens in early-stage ER+ breast cancer

31 Mar, 2023 | 13:37h | UTC

Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer – The ASCO Post

 

Commentary on Twitter

 

M-A | Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients

31 Mar, 2023 | 13:30h | UTC

Impact of Axillary Lymph Node Dissection and Sentinel Lymph Node Biopsy on Upper Limb Morbidity in Breast Cancer Patients: A Systematic Review and Meta-Analysis – Annals of Surgery

 

Study shows a slight breast cancer risk increase with progestogen-only birth control, comparable to combined oral methods

29 Mar, 2023 | 13:35h | UTC

Summary: A UK study and meta-analysis examined breast cancer risk linked to hormonal contraceptives, emphasizing progestagen-only contraceptives in premenopausal women. Utilizing a nested case-control design with the Clinical Practice Research Datalink (CPRD), a primary care database, the study included 9,498 women under 50 diagnosed with invasive breast cancer between 1996 and 2017, and 18,171 closely matched controls. The meta-analysis merged CPRD findings with 12 observational studies on progestagen-only preparations.

The results revealed that current or recent use of combined oral contraceptives, oral progestagen-only contraceptives, injectable progestagen, and progestagen intrauterine devices all led to a similar increase in breast cancer risk. The 15-year absolute excess risk associated with five years of oral combined or progestagen-only contraceptive use ranged from 8 per 100,000 users aged 16-20 to 265 per 100,000 users aged 35-39. The study concluded that both contraceptive types were linked to a slight breast cancer risk increase, and these risks must be weighed against the benefits of contraceptive use during childbearing years.

Article: Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis – PLOS Medicine

News Release: Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk – PLOS

Commentary: Expert reaction to study looking at the association between hormonal contraceptive use and breast cancer incidence – Science Media Centre

 

Review | Systemic therapy in HR+/HER2- early stage & metastatic breast cancer management

28 Mar, 2023 | 14:34h | UTC

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer – CA: A Cancer Journal for Clinicians

 

M-A | Supplemental breast cancer screening in women with dense breasts and negative mammography

10 Mar, 2023 | 14:12h | UTC

Supplemental Breast Cancer Screening in Women with Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis – Radiology (link to abstract – $ for full-text)

News Release: Breast MRI effective at detecting cancer in dense breasts – Radiological Society of North America

Commentary: Study Finds Breast MRI Superior vs Other Supplementary Screening Tests for Detecting Breast Cancer in Patients With Dense Breasts – The ASCO Post

 

Commentary on Twitter

 

M-A | Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer

9 Mar, 2023 | 14:06h | UTC

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials – The Breast

 

Cohort Study | Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer

2 Mar, 2023 | 12:56h | UTC

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer – JAMA Network Open

Commentary: Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment – HealthDay

 

Commentary on Twitter

 

RCT | Epirubicin + Paclitaxel vs Epirubicin and Cyclophosphamide followed by Paclitaxel in operable ERBB2-negative and lymph node–positive BC

27 Feb, 2023 | 12:55h | UTC

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial – JAMA Network Open

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.